Full Title
Phase II Investigation of Pembrolizumab in Combination with Bevacizumab and Oral Cyclophosphamide in Patients with High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyPurpose
Researchers want to see if combining pembrolizumab immunotherapy with standard treatment works well for people with ovarian cancer. The people in this study have ovarian cancer with minimal residual disease (MRD). MRD is a small amount of cancer cells remaining in the body after treatment.
If you take part in this study, you will get pembrolizumab plus bevacizumab and cyclophosphamide. Pembrolizumab works by boosting the ability of the immune system to find and kill cancer cells. Bevacizumab blocks the growth of the blood vessels tumors need to grow and spread. Cyclophosphamide is a chemotherapy drug.
Pembrolizumab and bevacizumab are both given intravenously (by vein). Cyclophosphamide is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have completed surgery and chemotherapy for high-grade non-mucinous epithelial ovarian cancer and have MRD after second-look surgery.
- Have not received prior treatment with an immunotherapy drug.
- Have recovered from the serious side effects of previous ant-cancer treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Rachel Grisham’s office at 646-888-4653.